Our Team
Big goals in the big apple
We come from different backgrounds, but we share the same belief: that science can change the world for the better. We exist to deliver life-saving cancer therapies through breakthroughs in drug discovery.
Our bios recount our academic credentials, but there’s a lot more to us. Our individual experiences shape who we are as a team, and together we’re passionate about making a difference.
We are supported by a premier group of investors and board members with a proven track record of building successful biotechnology companies. Our founders and scientific advisors are renowned for their seminal discoveries in cancer biology.
Jacqueline Gonzalez
Jacqueline has over 22 years of experience between corporate business and academia. In the last 15 years she has focused on supporting C-level executives. She takes great pride in her ability to juggle multiple responsibilities, her strong organizational skills, and great eye for detail while providing excellent customer service. Prior to joining Volastra, Jacqueline was at Weill Cornell Medicine where she supported our Founder, Lewis Cantley, Ph.D. for almost 9 years. Jacqueline worked closely with various groups within Cornell which included the Dean’s office, the Development office in supporting confidential philanthropic efforts as well as media relations, making sure all interviews were handled in accordance with Cornell’s rules. While under Dr. Cantley’s leadership, Jacqueline assisted in all recruitment efforts, hiring highly regarded junior and senior leadership personnel in the medical and scientific world. Jacqueline attended Westchester Community College as well as the School of Visual Arts where she pursued various acting and film studies.
Derek Cogan, Ph.D.
Derek has over 20 years of experience as a medicinal chemist that has covered all phases of drug discovery. After 15 years at Boehringer Ingelheim, he transitioned to build medicinal chemistry teams in biotech. Before taking the head of chemistry role at Volastra in 2019, he lead chemistry efforts at Bioverativ until its acquisition by Sanofi and Quentis Therapeutics. Derek obtained his B.S. at Boston College, his Ph.D. at the University of California at Berkeley, and did a post-doctoral fellowship at the University of California at Irvine.
Jasmina Prabhakara
|
Mia Jaffe, Ph.D.
Mia is an experienced bioinformatics scientist with a collaborative mindset and a deep passion for leveraging computational analyses for advancing drug discovery programs. Her background is wide ranging, and prior research projects have included developing novel functional genomics screening methodologies and analyzing various types of gene expression and proteomics data sets in both academic and industrial settings. Before joining Volastra, she was a Data Scientist at Kallyope, and she holds a B.S. in Biochemistry from the University of Washington and a Ph.D. in Genetics from Stanford University.
Ryan Schulz
Prior to joining the Volastra team, Ryan was at Black Diamond Therapeutics for 3.5 years, where he helped bring BDTX-4933, a reversible, brain-penetrant pan-RAF inhibitor, to IND-enabling preclinical studies. He also contributed to the implementation of a nascent large molecule program at BDTX using engineered cell lines expressing various wild type and mutant receptors.
Before his employment at BDTX, Ryan worked at Alexion Pharmaceuticals in the Protein Biochemistry group purifying and characterizing various antibodies and fusion proteins. His work there was critical for the discovery and development of two fusion proteins currently in clinical trials. Additionally, Ryan has experience at Coferon Inc., OSI/Astellas Pharmaceuticals, Enzo Life Sciences, and Brookhaven National Laboratory. He has a bachelor’s degree from Fairleigh Dickinson University and master’s degree from the University of Alabama at Birmingham.
Sarah Bettigole, Ph.D.
Sarah is a talented researcher with a deep knowledge of immunology and drug development. Prior to joining Volastra, Sarah co-founded Quentis Therapeutics, a company focused on targeting ER stress response pathways for cancer treatment. During her tenure she was director of biology and research project lead. She graduated from Tufts University with a bachelor’s in biology and earned her Ph.D. in immunology from Harvard University.
Jianmin Mao, Ph.D.
Jianmin brings over 20 years of industrial experience in drug discovery and development. Most recently, as Vice President of CMC at BeyondSpring Pharmaceuticals, he led the CMC team in Plinabulin NDA filings in the US and China. Prior to that, he served as Executive Director at Zikani Therapeutics (now Eloxx Pharmaceuticals), a company focused on developing therapies that treat rare and ultra-rare premature stop codon diseases. As Senior Director at Flatley Discovery Lab (FDL), he was instrumental in advancing the company’s two lead programs from preclinical stage into clinical Phase II. Before joining FDL, he contributed to the successful approval and commercialization of Baxdela® at Melinta Therapeutics. Prior to that, he worked on oncology drug development with ArQule Inc. (now Merck), where he contributed to multiple preclinical and clinical programs, most notably Derazantinib, Miransertib, and Tivantinib. Jianmin received his B.S. and Ph.D. in organic chemistry from Lanzhou University. He is an author of more than 30 peer-reviewed publications and is an inventor on 12 issued patents.
Song Chen, Ph.D.
Song is a motivated and versatile researcher with wide experience in tumor immunology, chemokine biology, and cell migration. Before joining Volastra, he did a short-term postdoctoral fellowship at the Massachusetts General Hospital and studied the role of chemokines and their receptors in the trafficking and function of T lymphocytes during the immune checkpoint blockade therapy. Song received his Ph.D. in pharmacology from the University of Michigan and his Ph.D. research aimed to understand how the topographic cues present in the extracellular matrix regulate cancer invasion and metastasis.
Michael Arensman, Ph.D.
Michael is a dedicated cancer researcher with experience ranging from tumor cell biology to immuno-oncology. Prior to joining Volastra, Michael worked at Pfizer, first as a postdoctoral fellow and then as a senior scientist. There he investigated tumor cell mechanisms of immunosuppression and worked to identify targets that could enhance anti-tumor immunity and increase T cell infiltration into tumors. Michael received his bachelor’s in cell and developmental biology from the University of California, Santa Barbara, and his Ph.D. in cellular and molecular pathology from the University of California, Los Angeles.
Diane Tager, RN, MBA
Diane is an experienced business developer with a deep knowledge of corporate strategy, operations and project management. Prior to joining Volastra, Diane was the director of equities and operations at Celgene, a Bristol Myers Squibb company. Before starting her career in the pharmaceutical and biotech industry, Diane was a registered nurse for a local health department. She graduated with a B.S./R.N. from Georgetown University and received her MBA from the University of Virginia Darden School of Business.
Kassoum Nacro, Ph.D.
Kassoum is a medicinal chemist with a big passion for drug discovery and drug hunting for the treatment of human ailments. Before joining Volastra Therapeutics, Kassoum worked in Discovery Chemistry at EDDC (ASTAR, Singapore) in early and late projects including the MNK project that led to the discovery of clinical candidate ETC-206. Prior to joining EDDC, Kassoum was a medicinal chemist at AMRI (now CURIA) where he contributed to the discovery of clinical candidate Liafensine. He received his Ph.D. in Organic Chemistry from Paul Sabatier University in Toulouse, France. He pursued a visiting fellowship at the National Cancer Institute of the NIH and was later appointed to Georgetown University, Lombardi Cancer Center as a faculty member.
Michael Su, Ph.D.
Michael is a pioneering biotech leader with deep expertise in drug discovery and translational medicine. Prior to joining Volastra, Michael was chief scientific officer of Decibel Therapeutics where he led the development of a gene therapy candidate for hearing loss. Before Decibel, Michael served as co-founder and senior vice president of research and development at Agios Pharmaceuticals. During his time at Agios, Michael led the team responsible for identifying oncogenic targets for the company’s lead mutant isocitrate dehydrogenase programs and led the discovery of the resulting drug candidates. He previously chaired the Agios-Celgene joint research collaboration from 2010 to 2013 and then guided drug discovery in the rare genetic diseases franchise. Michael also served as general director and vice president of the Biomedical Engineering Research Laboratory (BEL) at ITRI in Taiwan. Prior, he spent 14 years in a number of roles at Vertex Pharmaceuticals. Michael received his Ph.D. in biochemistry from Duke University and was a Helen Hay Whitney fellow in biochemistry and molecular biology at Harvard University.
Martha Rutkowski
Martha has extensive experience supporting C-level executives and takes pride in her strong organizational skills, great eye for detail and excellent customer service. Prior to joining Volastra, Martha worked as office manager at Avrio Health, where she ran office operations and coordinated leadership team activities around corporate objectives to ensure connectivity between programs. Before Avrio Health, Martha served as a senior administrative associate and human resource associate at Purdue Pharma L.P. for over 16 years. At Purdue, Martha provided administrative support to executive leaders and acted as a key liaison between the commercial organization and cross-functional corporate areas. Martha started her career at Boehringer Ingelheim as a human resources associate. She graduated with a bachelor’s from Iona College, a masters from the College of New Rochelle, and received her human resources certificate from Cornell University’s IRL School.
Alan Chiu, Ph.D.
Alan is a dynamic researcher with a wide range of experiences in modeling cancer and diabetes using next-generation in vitro models such as organoids and spheroids. Before joining Volastra, Alan’s research focused on the influence of mechanical and inflammatory cues on tumors and macrophage activity. He received his bachelor’s degree in biology from Harvard University and his Ph.D. in bioengineering from Cornell University.
Charles Hugh-jones, M.D., FRCP
Charles is an experienced biotech leader and a board-certified physician. Prior to joining Volastra, Charles served as the global chief medical officer at Allergan PLC, where he led complex interdisciplinary teams and supported the launch of novel medicines in multiple therapeutic areas. Before Allergan, Charles worked for Pfizer Oncology as their chief medical officer and had medical oversight of all late-stage drug development and commercialization activities. He began his career at Schering AG, Enzon Pharmaceuticals and Sanofi, where he held various positions of increasing responsibility. Charles received his bachelor’s in neuroanatomy and M.D. from the University of London. He went on to complete higher specialist training in diagnostic radiology.
Rumin Zhang, Ph.D.
Rumin is a seasoned drug hunter with an expertise in biophysics, biochemistry and pharmacology. Prior to joining Volastra, Rumin served as vice president of discovery at Rafael Pharmaceuticals, a company focused on developing therapies that target altered cancer metabolism, and head of research & senior director at Eternity Bioscience, a subsidiary of Hengrui Medicine. Before Eternity, Rumin was a senior principal scientist at Merck and Schering-Plough Research Institute. Rumin received his bachelor’s in biology and microbiology from Wuhan University and his Ph.D. in biophysics and biochemistry from SUNY at Buffalo.
Adriana Roopnariane, M.S.
Adriana is a scientist with extensive preclinical research and experimental design experience, spanning the continuum of drug discovery. She graduated with her master’s degree in Genetics from Pennsylvania State University. From 2010 to 2020, Adriana worked at Eli Lilly in several departments, most recently in the Translational Oncology department, where she supported MOA studies of two clinical stage assets.
Adriana joined Stelexis Therapeutics in January 2020 as a Research Scientist on the Cancer Stem Cell Platform team.
In her spare time, Adriana loves crafting.
Nada Elmansy, M.S.
Nada is a science researcher, passionate about contributing her part in helping cancer patients. Prior to joining Volastra, she worked at the Icahn School of Medicine at Mount Sinai as an Associate Researcher in the Hematology and Oncology department. Nada played a role in exploring different drugs and treatment options, including the targeting of hematopoietic stem cells in myelofibrosis patients. Prior to her work at Mount Sinai, Nada spent a little over a year working at the Children’s Cancer Hospital in Egypt, where she researched pediatric brain tumors. Nada completed her M.Sc. in Biotechnology at Georgetown University. During this time, she took part in a project examining genomic instability in Ewing Sarcoma.
Derek Rookhuizen, Ph.D.
Derek is a multi-faceted researcher with broad expertise ranging from innate immunity and cell biology to epigenetics. He’s passionate about investigating how ancient viral sequences in our genome can stimulate immunity and promote anti-tumor responses. During his postdoctoral studies at the Curie Institute in Paris, France, he discovered a new mechanism of host defense during infection that relies on innate detection of the host’s own genome to strengthen anti-microbial defenses. He pursued his Ph.D. training at the University of California, Berkeley where he demonstrated how innate sensing can program the magnitude and quality of T-dependent antibody responses, key elements of vaccine design.
Kenneth Hess, Ph.D.
Prior to joining Volastra, Ken worked in business development at I-Mab Biopharma, where he led oncology search & evaluation for the US and EU. Additional responsibilities included leading due diligences, commercial/financial analyses, and negotiation of partnership opportunities.
Prior to I-Mab, Ken held business development positions at Otsuka Pharma and Purdue Pharma, contributing to both scientific and commercial evaluations of assets of all stages (preclinical to marketed).
Ken began his career as a consultant at Defined Health (subsequently Cello Health and Lumanity), supporting biopharmaceutical and investment firms across therapeutic areas on a variety of strategic project types including opportunity assessments, indication prioritizations, gap analyses, and licensing scans.
Ken holds a B.A. in economics from Franklin & Marshall College, a Ph.D. in pharmacology from the Weill Cornell Graduate School of Medical Sciences, and an MBA from the S.C. Johnson Graduate School of Management at Cornell University.
Rachel Zolot Schwartz, MBA
Rachel brings over 15 years of commercial and business development experience both within the pharmaceutical industry as well as in consulting. Prior to joining Volastra, she worked in business development at Pfizer, where she led the commercial assessments for all oncology deals, notably including the $11B acquisition of Array BioPharma in 2019. During her time in business development, she also completed transactions to externalize medicines that had been deprioritized by Pfizer. In addition to business development, she held senior roles in commercial development and marketing, where she recently led the launch planning for ORGOVYX. She also spent time in Pfizer’s Portfolio Decision Analysis group supporting R&D investment allocation decisions to optimize value and improve R&D productivity across Pfizer’s portfolio. Before Pfizer, Rachel was a principal at Trinity Life Sciences consulting where she focused on licensing & acquisitions, brand strategy and portfolio optimization. She began her career in sales and marketing at Eli Lilly. Rachel received her MBA at the New York University Stern School of Business and holds an undergraduate degree from the University of Pennsylvania.
Rafael Depetris, Ph.D.
Rafael obtained a Ph.D. in Structural Biology from NYU, working at Stevan Hubbard’s laboratory on the topic of the intracellular regulation of the insulin signaling pathway. This was followed by postdoctoral work at Weill Cornell Medical College, focusing on the structural analysis of the HIV-1 envelope for vaccine design. He always had a great passion for pharmacology and for drug development, which led him to obtain a Senior Scientist position at the Pfizer Centers of Therapeutic Innovation. During this two year tenure, he acted as the point person for protein expression and purification and for the structural analysis of therapeutic antibodies for humanization and developability. Rafael subsequently was recruited to Kadmon to set up a Structure Based Drug Design (SBDD) group, which supported several small molecule development programs in the areas of immunology, immuno-oncology, cancer metabolomics and fibrosis. He stayed at Kadmon for almost eight years as Principal Scientist I and II, working in close collaboration with the Medicinal Chemistry and the Biology departments.
Aaron Phillips, Ph.D.
Aaron is a multi-faceted scientist with research experience ranging from cell engineering to single molecule analyses, as well as cell biology work in cancer, fibrosis and mitochondrial diseases. Prior to joining Volastra, Aaron worked at Inzen Therapeutics, a company developing therapies based on insights into cell death in disease. Aaron received his B.S. in chemistry from Union College and an M.S. in chemistry from Tufts University. Aaron completed his Ph.D. in cell and molecular biology at the Vilcek Institute of Graduate Biomedical Sciences at NYU in Agnel Sfeir’s lab, where he studied mitochondrial DNA replication and repair at the single molecule level.
Andrew DeCotiis, M.S.
|
Nazario Bosco, Ph.D.
Nazario is a molecular biologist by training and brings to Volastra years of experience in genetics, cytogenetics and cancer biology. Nazario recently worked at NYU Langone as a Senior Scientist where he studied the causes and consequences of chromosome gains and losses in solid tumors. He received his Ph.D. in genetics and molecular biology from the Sapienza University of Rome and did his postdoctoral training at The Rockefeller University working with Dr. Titia de Lange on deciphering how telomere dysfunction promotes genome instability.
Lyuben Tsvetkov, Ph.D.
Prior to joining Volastra, Lyuben worked in oncology drug discovery at Schrodinger across multiple assets, including leading the biology for the CDC7 kinase inhibitor pre-clinical program. Prior to Schrodinger, Lyuben worked in the Oncology R&D at GSK, where he focused on drug discovery in the ubiquitin dependent degradation pathways and translational research in immuno-oncology.
He started his career in the biotech industry at Rigel Pharm. in South San Francisco, CA were he was leading drug discovery efforts in the field of ubiquitin ligase inhibitors.
Lyuben completed his postdoctoral training at the Yale University School of Medicine in the departments of Genetics and Pathology, where his research interests were focused on the cell cycle regulation and the DNA damage checkpoint pathways.
He received an M.S. in cell biology from the Sofia Univ. and Ph.D. in molecular biology and biochemistry from the Institute of Molecular Biology in Sofia, Bulgaria.
Christina Eng, Ph.D.
Christina is an experienced and scientifically driven drug discovery leader. She has a deep knowledge of the biopharmaceutical industry and for more than 13 years has helped drive small and large molecule programs from target validation to post-clinical candidate nomination. Prior to joining Volastra, Christina was an associate research fellow and senior principal scientist at Pfizer, where she was responsible for leading a large, cross-functional team in the development of therapeutic proteins that promote immune co-stimulation in the tumor microenvironment. Christina first joined Pfizer as a postdoctoral fellow with Wyeth Research and helped investigate the role of molecules in cancer metabolism and catabolic activity. Christina received her bachelor’s in chemistry and biology from MIT and her Ph.D. in cell biology from Columbia University.
Bernardo Tavora, Ph.D.
Bernardo is a biomedical scientist with extensive experience in pre-clinical models of cancer biology to study tumor growth and metastasis. For his postdoctoral work at the Rockefeller University, Bernardo used an innovative in vivo system to identify genes required for metastatic progression. He received his Ph.D. from the University of London, where he generated multiple new mouse models to study the role of Focal Adhesion Kinase in tumor angiogenesis and resistance to therapies.
Cindy Oh
Cindy has a broad background in clinical research, with clinical operations and strategic project management experience spanning both early and late phase drug development. Prior to joining Volastra, she worked at Zentalis Pharmaceuticals, a biotechnology company developing targeted cancer therapeutics, and Sumitomo Pharma Oncology, a biopharmaceutical company with an oncology focus where she held roles with increasing responsibility. Cindy graduated from Brown University with a B.S. in Biology and a M.S. in Biotechnology.
Jonathan Havel, Ph.D.
Jonathan is a purpose-driven researcher with experience in tumor immunology, cancer cell signaling and high-throughput assay design. Prior to joining Volastra, he was a postdoctoral fellow at the Memorial Sloan Kettering Cancer Center, where he studied novel determinants of cancer immunotherapy response. He graduated from Lehigh University with a bachelor’s degree in biochemistry and earned a Ph.D. in molecular pharmacology from Emory University.
Reka Letso, Ph.D.
Reka is an experienced research lab manager with a strong background in molecular and cellular biology. Prior to joining Volastra, Reka was a lab manager/scientist at Inzen Therapeutics, where she led laboratory operations and a BSL2 laboratory build-out and worked on their Thanokine platform. She received her bachelor’s in molecular biology and biochemistry from Rutgers University and her Ph.D. in chemical biology from Columbia University.
Scott Drutman, M.D., Ph.D.
Scott is an oncologist physician scientist who is passionate about translating scientific discoveries into treatments for cancer patients.
Prior to joining Volastra, Scott worked in oncology clinical development at Regeneron Pharmaceuticals in both early and late development across multiple assets, including leading a first in class clinical program for REGN7075 (EGFRxCD28 bispecific) across multiple tumor types. In addition to driving clinical programs, Scott simultaneously worked in business development, where he was responsible for scientific and clinical diligence and strategy for the solid tumor oncology program.
Prior to Regeneron, Scott was an Instructor at The Rockefeller University, where his research program focused on immunology and human genetics.
Scott completed his postdoctoral fellowship at The Rockefeller University, his medical oncology clinical fellowship and additional training in early phase immuno-oncology at Memorial Sloan Kettering Cancer Center, and his internal medicine residency at New York-Presbyterian/Weill Cornell
He received an undergraduate degree from Reed College, an M.D./Ph.D. from NYU School of Medicine, and an M.S. in clinical and translational investigation from The Rockefeller University.
Joseph Avallone, CPA
Celia Andreu, Ph.D.
Prior to joining Volastra, Celia worked at Inspirna as a senior scientist and principal scientist of translational medicine. There, she designed and executed the biomarker strategy to support early clinical development of 2 first-in-class drugs targeting NSCLC and CRC. Celia received her undergraduate degree in Pharmacology and her Ph.D. in Neurobiology from University of Valencia in Spain. Prior to joining Inspirna, she was a postdoctoral fellow at Memorial Sloan Kettering Cancer Center where she studied the role of microRNAs in glioma. She has led numerous research projects that have been published in Nature, Nature Neuroscience and Cell. Celia was an EMBO and NYSTEM fellow recipient and was given the award for the best MSKCC Postdoctoral Research of the Year.
Rick Tourdot, Ph.D.
Rick is an interdisciplinary researcher with experience developing and employing computational models to answer complex biological questions. Prior to joining Volastra, Rick was a postdoctoral fellow at the Dana-Farber Cancer Institute where he studied the mechanisms governing cancer genome evolution. This included developing methods to reconstruct the complex genome structures found in many cancer cells. He earned a Ph.D. in chemical and biomolecular engineering from Penn working in Ravi Radhakrishnan’s lab, where he studied cell membrane tension and its relation to oncogenesis.
Aliasghar Mortazi, Ph.D.
Charles Hugh-jones, M.D., FRCP
Charles is an experienced biotech leader and a board-certified physician. Prior to joining Volastra, Charles served as the global chief medical officer at Allergan PLC, where he led complex interdisciplinary teams and supported the launch of novel medicines in multiple therapeutic areas. Before Allergan, Charles worked for Pfizer Oncology as their chief medical officer and had medical oversight of all late-stage drug development and commercialization activities. He began his career at Schering AG, Enzon Pharmaceuticals and Sanofi, where he held various positions of increasing responsibility. Charles received his bachelor’s in neuroanatomy and M.D. from the University of London. He went on to complete higher specialist training in diagnostic radiology.
Diane Tager, RN, MBA
Diane is an experienced business developer with a deep knowledge of corporate strategy, operations and project management. Prior to joining Volastra, Diane was the director of equities and operations at Celgene, a Bristol Myers Squibb company. Before starting her career in the pharmaceutical and biotech industry, Diane was a registered nurse for a local health department. She graduated with a B.S./R.N. from Georgetown University and received her MBA from the University of Virginia Darden School of Business.
Michael Su, Ph.D.
Michael is a pioneering biotech leader with deep expertise in drug discovery and translational medicine. Prior to joining Volastra, Michael was chief scientific officer of Decibel Therapeutics where he led the development of a gene therapy candidate for hearing loss. Before Decibel, Michael served as co-founder and senior vice president of research and development at Agios Pharmaceuticals. During his time at Agios, Michael led the team responsible for identifying oncogenic targets for the company’s lead mutant isocitrate dehydrogenase programs and led the discovery of the resulting drug candidates. He previously chaired the Agios-Celgene joint research collaboration from 2010 to 2013 and then guided drug discovery in the rare genetic diseases franchise. Michael also served as general director and vice president of the Biomedical Engineering Research Laboratory (BEL) at ITRI in Taiwan. Prior, he spent 14 years in a number of roles at Vertex Pharmaceuticals. Michael received his Ph.D. in biochemistry from Duke University and was a Helen Hay Whitney fellow in biochemistry and molecular biology at Harvard University.
Rachel Zolot Schwartz, MBA
Rachel brings over 15 years of commercial and business development experience both within the pharmaceutical industry as well as in consulting. Prior to joining Volastra, she worked in business development at Pfizer, where she led the commercial assessments for all oncology deals, notably including the $11B acquisition of Array BioPharma in 2019. During her time in business development, she also completed transactions to externalize medicines that had been deprioritized by Pfizer. In addition to business development, she held senior roles in commercial development and marketing, where she recently led the launch planning for ORGOVYX. She also spent time in Pfizer’s Portfolio Decision Analysis group supporting R&D investment allocation decisions to optimize value and improve R&D productivity across Pfizer’s portfolio. Before Pfizer, Rachel was a principal at Trinity Life Sciences consulting where she focused on licensing & acquisitions, brand strategy and portfolio optimization. She began her career in sales and marketing at Eli Lilly. Rachel received her MBA at the New York University Stern School of Business and holds an undergraduate degree from the University of Pennsylvania.
Scott Drutman, M.D., Ph.D.
Scott is an oncologist physician scientist who is passionate about translating scientific discoveries into treatments for cancer patients.
Prior to joining Volastra, Scott worked in oncology clinical development at Regeneron Pharmaceuticals in both early and late development across multiple assets, including leading a first in class clinical program for REGN7075 (EGFRxCD28 bispecific) across multiple tumor types. In addition to driving clinical programs, Scott simultaneously worked in business development, where he was responsible for scientific and clinical diligence and strategy for the solid tumor oncology program.
Prior to Regeneron, Scott was an Instructor at The Rockefeller University, where his research program focused on immunology and human genetics.
Scott completed his postdoctoral fellowship at The Rockefeller University, his medical oncology clinical fellowship and additional training in early phase immuno-oncology at Memorial Sloan Kettering Cancer Center, and his internal medicine residency at New York-Presbyterian/Weill Cornell
He received an undergraduate degree from Reed College, an M.D./Ph.D. from NYU School of Medicine, and an M.S. in clinical and translational investigation from The Rockefeller University.
Investors
